Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

14 mai 2026 09h41 HE | Source: Research and Markets

KLK2-Targeted Immunotherapies Pipeline Competitor Analysis Report 2026: Active R&D Programs by R&D Phase and Profile of Targeted Immunotherapies by Drug Modality

Dublin, May 14, 2026 (GLOBE NEWSWIRE) -- The "Pipeline of KLK2-Targeted Immunotherapies" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report about...
14 mai 2026 09h40 HE | Source: Research and Markets

Glypican-3 (GPC3) Targeted Therapy Pipeline Competitor Analysis Report 2026: Active R&D Programs by R&D Phase and Profile of Targeted Immunotherapies by Drug Modality

Dublin, May 14, 2026 (GLOBE NEWSWIRE) -- The "Glypican-3 (GPC3) Targeted Therapy: a Competitor Analysis" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence...
14 mai 2026 09h39 HE | Source: Research and Markets

PD-L1 X 4-1BB (CD137) Bispecific Antibodies Pipeline Competitor Analysis Report 2026: Active R&D Programs by R&D Phase and Profile of Bispecific Antibodies by Drug Modality

Dublin, May 14, 2026 (GLOBE NEWSWIRE) -- The "Pipeline of PD-L1 x 4-1BB (CD137) Bispecific Antibodies" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence...
14 mai 2026 09h35 HE | Source: Research and Markets

Folate Receptor alpha (FRa) Targeted Therapy Pipeline Competitor Analysis Report 2026: Active R&D Programs by R&D Phase and Profile of Targeted Immunotherapies by Drug Modality

Dublin, May 14, 2026 (GLOBE NEWSWIRE) -- The "Folate Receptor alpha (FRa) Targeted Therapy: a Competitor Analysis" report has been added to ResearchAndMarkets.com's offering.This competitive...
14 mai 2026 09h28 HE | Source: Research and Markets

DLL3-Targeted Immunotherapy Pipeline Competitor Analysis Report 2026: Active R&D Programs by R&D Phase and Profile of Targeted Immunotherapies by Drug Modality

Dublin, May 14, 2026 (GLOBE NEWSWIRE) -- The "DLL3-Targeted Immunotherapy: a Competitor Analysis" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report...
07 mai 2026 09h08 HE | Source: Research and Markets

Bi-Specific MAbS Market Research Report 2026: $21.83 Bn Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

Dublin, May 07, 2026 (GLOBE NEWSWIRE) -- The "Bi-Specific MAbS Market Report 2026" has been added to ResearchAndMarkets.com's offering. The bi-specific monoclonal antibodies (mAbs) market is...
03 mai 2026 20h00 HE | Source: AGC Biologics, Inc.

Novelty Nobility Taps AGC Biologics to Further Develop Bispecific Drug Candidate

AGC Biologics expands its partnership with Novelty Nobility to manufacture a bispecific antibody in Japan.
21 avr. 2026 04h49 HE | Source: Research and Markets

Bispecific Antibody Drug Conjugates Market Landscape Report 2026: A $2 Billion Opportunity by 2030 with the 1st Approved BsADC by 2028 - Clinical Trials, Regulatory Approvals, Development Platforms

Dublin, April 21, 2026 (GLOBE NEWSWIRE) -- The "Bispecific Antibody Drug Conjugates Clinical Trials, Regulatory Approvals, Development Platforms & Market Opportunity Insight 2026" report has...
21 avr. 2026 04h34 HE | Source: Research and Markets

Bispecific Antibody Market Landscape Report 2026: A Potential $60 Opportunity by 2031 - Insight on More than 550 Clinical Trials - Antibody Dosage, Patent, Price, Sales & Outlook

Dublin, April 21, 2026 (GLOBE NEWSWIRE) -- The "Bispecific Antibody Market Opportunity, Antibody Dosage, Patent, Price, Sales & Clinical Trials Outlook 2031" report has been added to ...
14 avr. 2026 21h00 HE | Source: Shanghai EpimAb Biotherapeutics Co., Ltd.

EpimAb Biotherapeutics to Present a Novel Prodrug T-Cell Engager (ProTCE) Platform at the 2026 American Association for Cancer Research Annual Meeting

SHANGHAI, April 15, 2026 (GLOBE NEWSWIRE) -- EpimAb Biotherapeutics, a clinical stage biotechnology company specializing in the development of bispecific antibodies and T-cell engagers, is pleased...

Page suivante